ASSOCHAM estimates that the spurious drug market is growing at 25% annually. In fact, the Organization for Economic Cooperation and Development's latest figures say 75% of fake drugs supplied the world over have their origins in India.
The Chennai based Kinship Technologies Private Ltd has launched a new product called iDERT (Integrated Data Extraction and Reporting Tool) which will enable Pharmaceutical and Biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company has received approval from United States Food and Drug Administration (USFDA) for marketing approval for OraVerse (phentolamine mesylate).
United States Food and Drug Administration (FDA) has approved Eli Lilly Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
Karnataka government has appointed Dr Bharatesh R Jagashetty, as the Drugs Controller for Government of Karnataka with effect from May 1, 2008.
BioSyent Inc. has established a new Hospital Products Division focused on licensing or acquiring pharmaceutical products used primarily in a hospital setting, and marketing those products across Canada.
U.S.-India Business Council and Caterpillar, Inc. is organizing a roundtable briefing on 'Investment & Growth Opportunities in Tamil Nadu' with Mr. L.K. Tripathy Chief Secretary Government of Tamil Nadu on May 19th 2008 at 8:30 am – 10:30 am at the St. Regis San Francisco, 125 Third Street , San Francisco, CA 94103
CRAMS Hold Huge Prospects for Indian Pharma Units Contract Research and Manufacturing Services utilising excess manufacturing capacities.They have (CRAMS), is becoming one of the most promising moved into providing drug discovery, custom chemical opportunities for the Indian pharmaceutical industry…[English]-[French]-[Spanish]
Ranbaxy Laboratories Ltd. has tie-up with global pharma major Merck & Co. to drug discovery and development. The strategic product development agreement calls for joint research to develop clinically validated anti-bacterial and anti-fungal drug candidates.
US-based Merck has received patent approval from the Indian Patent Office for two of its upcoming drugs for dyslipidemia and obesity. The two new patented drugs are in final stages of trial and are yet to receive the Drug Controller General of India’s (DCGI) approval.
The US Food and Drug Administration has approved a new formulation of the genetically engineered version of Factor VIIa, a plasma protein essential for the clotting of blood.
Aurobindo receives approval from Medicines Control Council (MCC) to market nine products in South Africa. The products are said to have a generic market size of 165 million South African brands in the local market
Quintiles Transnational Corp. has signed an agreement to acquire Eidetics, a privately held decision-analytics and market research consulting firm located in Boston as part of its expanding Quintiles Consulting business.
The Institute for OneWorld Health, a US-based non-profit pharmaceutical company which develops drugs for infectious diseases in the developing world has formed a Strategic Advisory Board to support the iOWH Diarrhoeal Disease Program (DDP).
US Food and Drug Administration has approved updated labeling for Abilify, a drug made jointly by Bristol-Myers Squibb and Japan’s Otsuka Pharmaceuticals.
The Ayurveda drug industry is growing at an estimated 15% in India and Maharashtra state Rs 16-crore Ayurved Cluster in Maharashtra by the Central Government.
Antibiotics and anti-bacterial drugs dominated domestic pharma retail market in the first quarter (January-March) of the financial year. These include Augmentin (manufactured by GlaxoSmithKline), Mox (Ranbaxy), Zifi (FDC Ltd) and Taxim (Alkem).
Jubilant Organosys has acquired 100 per cent stake in Speciality Molecules Pvt. Ltd for Rs 199.5 million on a debt free, cash free basis.
Parliamentary Consultative Committee of Chemicals and Fertilizers Ministry expresses concern over the delay in finalization of New Pharmaceutical Policy